Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Bought by Principal Financial Group Inc.

Principal Financial Group Inc. grew its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 9.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 96,835 shares of the company’s stock after purchasing an additional 8,213 shares during the quarter. Principal Financial Group Inc.’s holdings in Amneal Pharmaceuticals were worth $767,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in AMRX. Chartwell Investment Partners LLC boosted its holdings in Amneal Pharmaceuticals by 21.3% in the third quarter. Chartwell Investment Partners LLC now owns 82,410 shares of the company’s stock worth $686,000 after acquiring an additional 14,477 shares in the last quarter. Versor Investments LP boosted its stake in Amneal Pharmaceuticals by 191.3% in the 3rd quarter. Versor Investments LP now owns 40,200 shares of the company’s stock worth $334,000 after purchasing an additional 26,400 shares in the last quarter. Aigen Investment Management LP purchased a new stake in Amneal Pharmaceuticals during the 3rd quarter worth approximately $213,000. Victory Capital Management Inc. increased its stake in Amneal Pharmaceuticals by 58.7% during the 3rd quarter. Victory Capital Management Inc. now owns 99,215 shares of the company’s stock valued at $825,000 after purchasing an additional 36,700 shares in the last quarter. Finally, Gladius Capital Management LP purchased a new position in shares of Amneal Pharmaceuticals in the third quarter worth $37,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Trading Down 2.3 %

Shares of AMRX stock opened at $8.76 on Friday. Amneal Pharmaceuticals, Inc. has a 12-month low of $5.18 and a 12-month high of $9.48. The business’s 50 day moving average is $8.18 and its two-hundred day moving average is $8.34. The company has a market capitalization of $2.71 billion, a P/E ratio of -12.88 and a beta of 1.10.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Friday, February 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The company had revenue of $730.52 million for the quarter, compared to analyst estimates of $708.21 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. On average, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, Director Gautam Patel sold 62,590 shares of the business’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $8.01, for a total transaction of $501,345.90. Following the transaction, the director now owns 1,968,886 shares of the company’s stock, valued at approximately $15,770,776.86. The trade was a 3.08 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 240,000 shares of company stock worth $2,004,000. Corporate insiders own 26.56% of the company’s stock.

Analyst Upgrades and Downgrades

AMRX has been the subject of several research reports. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $9.00 to $12.00 in a research note on Monday, February 24th. Barclays boosted their target price on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday. Piper Sandler increased their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Finally, StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $10.80.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.